In this issue:
- ESMO clinical practice guideline for the management of HCC
- Anlotinib + penpulimab vs sorafenib for first-line treatment of unresectable HCC
- Addition of tiragolumab to atezolizumab + bevacizumab in patients with HCC
- Liver cancer in 2021: Global Burden of Disease study
- Optimising treatment selection for early HCC
- Ipilimumab + anti-PD-1/ PD-L1 combination therapy in advanced HCC
- Is the current surveillance strategy suitable for all patients and disease types?
- Abbreviated MRI vs ultrasound for detecting early-stage HCC
- Immunotherapy before liver transplant in high-risk patients with HCC
Please login below to download this issue (PDF)